13:45 29/09/2016 Pfizer Inc. (NYSE:PFE) Prevnar 13, Losing Sales Momentum?
Pfizer Inc. (NYSE:PFE) Prevnar 13, Losing Sales Momentum?
Market Exclusive - 44 minutes ago
Furthermore, the company's vaccine portfolio has seen a consistent sequential growth in sales in 2015. For the full-year, the portfolio had recorded a 44% sales increase.

12:15 29/09/2016 Pfizer Inc. (PFE) Stock Rating Reaffirmed by Bank of America Corp.
Pfizer Inc. (PFE) Stock Rating Reaffirmed by Bank of America Corp.
BBNS - 2 hours ago
Pfizer logo Pfizer Inc. (NYSE:PFE)'s stock had its “buy” rating reaffirmed by investment analysts at Bank of America Corp.
Significant Ownership Change: Santa Barbara Asset Management LLC Boosted ... - Post News
Viewing Major Stock of Yesterday- Pfizer Inc.'s (PFE) - Hot Stocks Point

20:18 28/09/2016 Pfizer: No Buy Signal After The Dip
Pfizer: No Buy Signal After The Dip
Seeking Alpha - 18 hours ago
Pfizer is down sharply over the last couple of months culminating with a decision to not split into two companies. The company has a stock buyback plan, but chooses to use larger amounts of cash on making acquisitions such as paying $14 billion for ...
Plan by Pfizer to Split Into Two Companies Abandoned - CDA News

14:44 28/09/2016 Pfizer Inc. (PFE) Given "Buy" Rating at Bank of America Corp.
Pfizer Inc. (PFE) Given "Buy" Rating at Bank of America Corp.
The Cerbat Gem - 23 hours ago
Pfizer Inc. logo Bank of America Corp. reaffirmed their buy rating on shares of Pfizer Inc. (NYSE:PFE) in a research note released on Tuesday morning.
Pfizer Inc. (NYSE:PFE) Receives Consensus Recommendation of "Buy" from Analysts - Community Financial News
Pfizer Inc. (NYSE:PFE) Earns Consensus Hold Rating - Review Fortune

13:45 28/09/2016 Pfizer (PFE) Closes Medivation (MDVN) Acquisition
Pfizer (PFE) Closes Medivation (MDVN) Acquisition
StreetInsider.com - Sep 28, 2016
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Medivation, Inc.(NASDAQ: MDVN). As of the tender offer expiration, 115,574,041 shares of Medivation common stock were validly tendered, representing approximately ...
Pfizer Inc. (NYSE:PFE) Acquisition Of Medivation, Inc. (NASDAQ:MDVN) To Close ... - Market Exclusive
Active Eye Catching Stocks- Pfizer Inc. (NYSE:PFE), First Horizon National ... - Seneca Globe

18:10 27/09/2016 Pfizer's 9% Decline Gives Dividend Investors Buying Opportunity
Pfizer's 9% Decline Gives Dividend Investors Buying Opportunity
Seeking Alpha - Sep 27, 2016
Pfizer stock has taken a dip since the company announced it would not break itself up, preferring instead to remain a single entity.

8:52 27/09/2016 You Can't Ignore This News on Pfizer Inc. (PFE) Stock
You Can't Ignore This News on Pfizer Inc. (PFE) Stock
Income Investors - Sep 27, 2016
Pfizer Inc. (NYSE:PFE) has finally decided what investors wanted to hear. The world's second-largest pharmaceutical company has given up the idea to split its business, ending years of uncertainty and speculations which had surrounded PFE stock.
Pfizer Inc. (PFE) Sees Unusually-High Trading Volume Following Dividend ... - The Cerbat Gem
Analyst Ratings Worth Watching Pfizer Inc. (NYSE:PFE), Ford Motor Company (NYSE:F) - Review Fortune

12:15 26/09/2016 Pfizer decides against split-up; more deals seen likely
Pfizer decides against split-up; more deals seen likely
Reuters - Sep 26, 2016
Jonas expects Pfizer to follow its decision to buy Medivation Inc (MDVN.O) for $14 billion with more deals of "that size or smaller.
Will Pfizer Inc.'s (PFE) Non-Split Policy be Beneficial for the Company? - TCC
Pfizer Throws Out Plan to Split Into Two Companies - Wall Street Journal

14:04 15/09/2016 Better Buy: Pfizer Inc. vs. AbbVie Inc.
Better Buy: Pfizer Inc. vs. AbbVie Inc.
Motley Fool - Sep 15, 2016
If it sounds like Pfizer is trying to buy its way to growth, it's because that's exactly what the company is attempting to do.

13:56 15/09/2016 OncoImmune Announces Option and License Agreement with Pfizer Inc.
OncoImmune Announces Option and License Agreement with Pfizer Inc.
Business Wire (press release) - Sep 15, 2016
ROCKVILLE, Md.--(BUSINESS WIRE)--OncoImmune, Inc. today announced that it has entered into an exclusive option and license agreement with Pfizer Inc. (NYSE: PFE) for ONC-392, a novel, differentiated preclinical anti-CTLA4 monoclonal antibody in a ...
Pfizer Seals License Deal with OncoImmune For Monoclonal Antibody ONC-392 In ... - Post News